PREVALENCE OF LINEZOLID-RESISTANT VANCOMYCIN-RESISTANT ENTEROCOCCUS SPECIES (LRVRE) IN CLINICAL ISOLATES FROM TERTIARY CARE HOSPITAL OF NORTH INDIA – A REAL THREAT

IntroLinezolid, an oxazolidinone antibiotic, was introduced early in 2000 as a new therapeutic option against gram positive cocci including vancomycin resistant enterococci (VRE). People are using linezolid alternative VRE due to which resistance is increasing rapidly leading failure of VRE. So the aims and objectives present study determine prevalence linezolid-resistant (LRVRE) clinical isolates.MethodsStudy performed from 1st January 2021 31st July 2022 Max super speciality hospital, Shalimar Bagh, New Delhi, India. Total 961 isolates urine, blood pus samples were included. Identification sensitivity conducted by vitek-2 compact automated system interpreted according laboratory standards institute guidelines.FindingsTable 1: Sensitivity pattern among isolatesDiscussionOut total 136 (14%) LRVRE. Prevalence LRVRE 116 (13%), 15 (25%) 5 (13%) respectively. higher isolates.ConclusionPrevalence it very alarming condition. Several factors contributing antibiotic have been described prolonged exposure antibiotics most striking. Therapeutic options limited for treatment Worldwide surveillance judicious use required. Linezolid, isolates. Study guidelines. Table Out